Thank you, Richard. So, over to a quick R&D update. I will begin with a brief presentation on the top line. Final results from the 52-week phase three ANOVA two study, which was recently completed and announced yesterday. The study included a total of 135 participants on stable doses of standard of care at baseline. Of these, 81 were new patients in the trial, and 54 were rollover patients from 24 weeks of randomized treatment with CAM2029 or placebo in the ANOVA number one study.
For placebo patients, we had two baselines: the standard of care baseline. So, entering the study on a standard of care and the placebo baseline after 24 weeks of receiving placebo, primary endpoints of the study were safety and tolerability over 52 weeks and secondary efficacy endpoints included. Changes from baseline in biochemical responses, symptom scores, quality of life, and patient and treatment satisfaction. Starting with the efficacy endpoints. Here are the response rates for insulin growth factor one (IGF-1), below or equal to one times the upper limit of normal after one year of treatment with CAM2029 versus the standard of care at baseline. Here, the standard of care is either a long-acting intramuscular, a cutaneous or a latrodect type depot, or 'autogel', as it's called in Europe, in newly studied patients mostly consisting of uncontrolled patients on stable doses of standard care. There was a significant increase in the response rate of 22.8% after switching to treatment with CAM2025 for 52 weeks. The improvement represented a key outcome of the Nova 2 study for rollover patients, who were generally biochemically controlled on stable doses of standard of care at the start of the study.
These remained well controlled after switching to treatment with CAM2029 overall, also including placebo patients from occurring over one. There was an increase in the response rate of 12.7% from baseline to the end of treatment with CAM2029. If we look specifically at the placebo patients in the study, they were well controlled with high IGF-1 response rates at standard of care and remained controlled until the end of treatment with CAM2029. However, during the placebo period, a majority of these patients lost their biochemical response. Importantly, 68.5% of them regained response during treatment with CAM2029.
These results support the long-term efficacy of CAM2029 in biochemically controlled and uncontrolled patients, as well as patients initiating treatment after brief interventions or post previous treatment episodes. Moving over to symptoms and looking at the full population. Remember, this includes the rollover patients who received a placebo during the first six months. As you can see in the graph, the symptom burden score estimated by the Acromegaly Index of Severity (AIS) score continuously improved on treatment with CAM2029 compared to standard of care at baseline. In addition to the improved AIS score, we also saw an increase in the number of patients who had no acromegaly symptoms after switching to CAM2029, with no recurrence or breakthrough symptoms at the end of the dosing intervals.
So now, moving on to patient-reported outcomes, starting with quality of life. And as you can see in the figure here, there was a significant improvement in the recall, total, and psychological scores after switching to CAM2029. Note for the context here that these patients were all on stable doses of standard of care before switching. Continuing with patient-reported treatment satisfaction compared to standard of care at baseline. The graph on the left-hand side shows significant improvements in the validated Treatment Satisfaction Questionnaire for Medication (TSQM) convenience, effectiveness, and global satisfaction scores.
The side effect score also numerically improved compared to standard of care. However, this effect was not statistically significant. Finally, on the right-hand side here, the patient satisfaction score clearly favored CAM2029, with the majority of patients rating the treatment as better than their previous one, and indeed, 56 patients rating it as much better. So finally, moving over to the safety of CAM2029, it was generally well tolerated with a safety profile consistent with the standard of care. Most adverse events were mild or moderate, grade 1 or 2 in intensity, with transient injection site reactions and gastrointestinal events being the most frequent observations.
No severe adverse events related to CAM2029 were observed in the trial. One serious adverse event, a case of congestive heart failure of moderate intensity, was reported in a rollover placebo patient. However, this was resolved, and the patient continued treatment with CAM2029 throughout the trial. Two patients discontinued treatment due to adverse events, one case of mild depression, and one case of mild injection site reaction. Finally, no new safety signals were noted in adverse events, ECGs, or laboratory tests. In summary, we are very pleased with the Camurus topline results, demonstrating a safety profile consistent with standard of care and compelling data on biochemical and symptom control during the 52 weeks of treatment, alongside significant improvements in patient reported outcomes. Detailed results will be presented in an upcoming meeting or meetings and future publications. Of course, based on the combined scientific evidence from the Renovo program, we believe CAM2029, if approved, has the potential to become a new standard treatment for patients with acromegaly. Combining convenient, once-monthly self-administration with durable efficacy and, of course, a safety profile. We continue making good progress in the CAM2029 program across the treatment indications of acromegaly, castration-resistant pancreatic neuroendocrine tumors, and polycystic liver disease.
And I'm looking forward to several key milestone events over the coming quarters, including the FDA approval decision in acromegaly by the date of 21st of October 2024, and a planned launch of Oclaiz™ in the US around the end of the year in GEP-NET or gastric pancreatic neuroendocrine tumors. We are expecting to finalize the core phase of the Sorrento study in H1 2025, and thereafter report topline results. This could allow for an NDA approval submission, I should say, to the FDA sometime in the second half of next year, and applications in other geographies to follow. So finally, topline results from the Positano study and PLD are expected early 2025. In advance of the planned US launch of Oclaiz™.
We have been active, very active, in sharing scientific evidence from the Renovo program, and this has included several presentations, both oral and posters, at the leading endocrinology conferences ACC and Endo during the quarter. We also arranged a well-attended and appreciated satellite symposium about new emerging treatments of acromegaly, including CAM2029, at the EC in Stockholm in May. So, summing up the second quarter. I'm pleased with the continued strong performance of our teams commercially, as well as in development and the significant progress that we have made. During the quarter, Buvidal sales grew, and were enforced across the markets in the EU, MENA, and Australia because the uptake was also growing nicely in the US.
Our pipeline continued to advance with significant events in terms of receiving MAA by EMA. And in parallel, we accelerated preparations for launch and the establishment of our US organization, and also advanced early pipeline programs, including the once-monthly semaglutide project. As a result of the solid performance to date, we reiterate our guidance and expect to finalize. As John said earlier, in the mid to high end of the previous interval. So, with that said, thank you everyone for listening. And now, please take over the call for the Q&A session.